Skip to main content

Table 1 Summary of diagnostics for heartworm (Dirofilaria immitis) in dogs from Australia

From: Mosquito-borne heartworm Dirofilaria immitis in dogs from Australia

Animal (dogs)

Immunology

Parasitology

Molecular diagnostics (real-time PCR)

 

Heartworm prevention

FVS-CN#

Age (yrs)

Witnessa

DiroCHEKb

Knott’s test

Dog (Ct)c

Filaria (Mff#/ml)d

D. immitis (Mff#/ml)e

Clinical signs

Compliancef

Active

1

6.0

Positive

Positive

Positive

7

Inconsistent

na

2

9.0

Positive

Positive

Positive

Present

Yes

Selamectin

3

2.0

Positive

Positive

Positive

27.6

10

14

na

na

4

7.5

Positive

Positive

Positive

35.0

165

147

Present

na

na

5

3.0

Positive

Positive

Positive

31.1

10

9

na

na

6

6.7

Positive

Positive

Positive

26.8

Yes

Milbemycin oxime

7

8.0

Positive

Positive

Positive

26.4

835

571

Yes

Ivermectin

8

10.0

Positive

Positive

Positive

24.9

215

204

na

na

9

3.8

Positive

Positive

Positive

26.2

118

52

Yes

Milbemycin oxime

10

5.1

Positive

Positive

Positive

27.7

46

15

inconsistent

na

11

na

Positive

Positive

Positive

24.5

23,376

60,527

inconsistent

na

12

2.8

Positive

Positive

Positive

30.2

24

460

Yes

Moxidectin

13

2.0

Positive

Negative

Positive

24.3

126

77

Present

inconsistent

na

14

4.0

Positive

Positive

Positive

32.9

3

0

na

na

15

7.0

Positive

Positive

Positive

22.4

912

610

na

na

16

2.0

Positive

Positive

Positive

23.0

940

261

na

na

17

3.0

Positive

Positive

Positive

24.9

165

518

na

na

18

2.0

Positive

Negative

Positive

25.2

124

239

na

na

19

2.0

Positive

Positive

Positive

24.6

34

261

Present

Yes

Milbemycin oxime

20

3.0

Positive

Positive

Positive

26.3

1,184

3,471

na

na

21

2.0

Positive

Positive

Positive

28.6

36

130

Yes

Milbemycin oxime

22

13.0

Positive

Positive

Positive

28.2

70

52

Present

Yes

Milbemycin oxime

23

2.0

Positive

Positive

Positive

28.8

60

416

Yes

Milbemycin oxime

24

3.0

Positive

Positive

Positive

38.8

1

77

na

na

25

5.0

Positive

Positive

Positive

26.6

4,543

8,042

Present

inconsistent

na

26

3.0

Positive

Positive

Positive

24.5

58

319

inconsistent

na

27

3.0

Positive

Positive

Positive

34.1

16

157

inconsistent

na

28

10.0

Positive

Positive

Positive

28.8

11,214

1,478

inconsistent

na

29

2.0

Positive

Positive

Positive

36.7

12

na

na

30

10.0

Positive

Positive

Positive

24.3

2,022

9,551

Yes

Ivermectin

31

7.0

Positive

Positive

Positive

23.9

177

217

na

na

32

6.1

Positive

Positive

Positive

24.1

15

321

Yes

Milbemycin oxime

33

na

Positive

Positive

Positive

28.8

41

45

Present

inconsistent

Ivermectin

34

5.5

Positive

Positive

Positive

23.7

8,745

15,976

Present

Yes

Milbemycin oxime

35

6.0

Positive

Positive

Positive

37.4

198

320

n/a

na

36

4.0

Positive

Positive

Positive

24.8

44,966

1,866

n/a

na

37

2.1

Positive

Positive

Positive

35.6

31

5,717

Yes

Milbemycin oxime

38

7.0

Positive

Positive

Positive

28.8

142

4,505

Yes

Moxidectin

39

1.8

Positive

Positive

Positive

27.4

773

276

Yes

Milbemycin oxime

  1. aIn-clinic Witness Dirofilaria® (Zoetis, Australia), a Rapid Immuno-Migration (RIM®) Assay for detection of adult female D. immitis (heartworm) antigen in dogs
  2. bDiroCHEK® (Zoetis, Australia) an enzyme-linked immunosorbent assay (ELISA) for the detection of adult D. immitis antigen
  3. cCanine ß-actin real-time PCR assay for sample adequacy evaluation, Ct <30 is considered adequate (n = 28, 72 %)
  4. dArthropod-borne filarioids high-resolution melt (HRM) real-time PCR assay targeting filarioid mitochondral 12S rRNA gene, reported as microfilaria (Mff) in ml of blood
  5. e D. immitis species-specific real-time PCR targeting cox1 gene fragment, reported as microfilaria (Mff) in ml of blood
  6. fRigorous compliance (Yes) was noted if client indicated year round administration with appropriate product, ‘inconsistent’ compliance if heartworm preventions were missed or intermittently administrated or incorrect dose administered, and ‘na’ if such information was not available or was unknown